Value is all about what a company is worth versus what price it is
available for. If you went into a grocery store and all the bananas were on sale
at half price, they could be considered
INTRINSIC VALUE BASED ON FUTURE CASH FLOWS
It is not possible to calculate the future cash flow value for
Surface Oncology. This is due to cash flow or dividend data being
unavailable. The share price is
PRICE RELATIVE TO MARKET
We can also value a company based on what the stock market is willing to pay for
it. This is similar to the price of fruit (e.g. Mangoes or Avocados) increasing
when they are out of season, or how much your home is worth.
The amount the stock market is willing to pay for
is considered below, and whether this is a fair price.
Price based on past earnings
Surface Oncology's earnings available for a low price, and how does
this compare to other companies in the same industry?
Surface Oncology is not considered high growth as it is expected to be loss making for the next 1-3 years.
Surface Oncology's revenue is expected to decrease over the next 1-3 years, this is not considered high growth.
Past and Future Earnings per Share
The accuracy of the analysts who estimate the future performance data can
be gauged below. We look back 3 years and see if they were any good at
predicting what actually occurred. We also show the highest and lowest estimates
looking forward to see if there is a wide range.
Surface Oncology's performance over the past 5 years by checking for:
Has earnings increased in past 5 years? (1 check)
Has the earnings growth in the last year exceeded that of the
industry? (1 check)
Is the recent earnings growth over the last year higher than the average annual growth over the
past 5 years? (1 check)
Is the Return on Equity (ROE) higher than 20%? (1 check)
Is the Return on Assets (ROA) above industry average? (1 check)
Has the Return on Capital Employed (ROCE) increased from 3 years ago? (1 check)
The above checks will fail if the company has reported a loss in the most recent
earnings report. Some checks require at least 3 or 5 years worth of data.
has a total score of
0/6, see the detailed checks below.
Note: We use GAAP Net Income excluding extraordinary items in all our calculations.
A company's financial position is much like your own financial position,
it includes everything you own
The boxes below represent the relative size of what makes up
Surface Oncology's finances.
The net worth of a company is the difference between its assets and liabilities.
Surface Oncology is able to meet its short term (1 year) commitments with its holdings of cash and other short term assets.
Surface Oncology's cash and other short term assets cover its long term commitments.
This treemap shows a more detailed breakdown of
Surface Oncology's finances. If any of them are yellow this
indicates they may be out of proportion and red means they relate to one of the
Liabilities and shares
The 'shares' portion represents any funds contributed by the owners (shareholders) and any profits.
Low level of unsold assets.
Surface Oncology has no debt, it does not need to be covered by short term assets.
Nearly all companies have debt. Debt in itself isn’t
however if the debt is too high, or the company can’t afford to pay the interest
on its debts this may have impacts in the future.
The graphic below shows equity (available funds) and debt, we ideally want to
see the red area (debt) decreasing.
If there is any debt we look at the companies capability to repay it, and
whether the level has increased over the past 5 years.
Management is one of the most important areas of a company. We look at
unreasonable CEO compensation, how long the team and board of directors have
been around for and insider trading.
TENURE AS CEO
Mr. J. Jeffrey Goater, also known as Jeff, M.S., M.B.A, CFA has been the Chief Executive Officer and Director of Surface Oncology, Inc. since February 12, 2018 and is its President. Mr. Goater served as the Chief Business Officer of Surface Oncology, Inc. since February 7, 2017 until February 12, 2018 and Secretary from February 2017 to September 2018. Mr. Goater served as a Consultant of Voyager Therapeutics, Inc. since December 31, 2016. Mr. Goater served as the Chief Financial Officer at Voyager Therapeutics, Inc. from February 2, 2016 to December 31, 2016 and served as its Principal Financial & Accounting Officer until December 31, 2016. He served as a Senior Vice President of Finance and Business Development at Voyager Therapeutics, Inc. from April 2015 to February 2, 2016. He served as Vice President of Business Development at Voyager Therapeutics, Inc. from 2014 to April 2015. He served as an Equity Analyst at Cowen and Company, LLC, Research Division. He has nearly 15 years of business development and financial experience in the biotech industry. He served as the Head of business development at Synageva BioPharma following nine years on Wall Street. He served as Managing Director of Evercore Partners, where he focused on strategic advisory in the life sciences sector. At Evercore, he advised on $100+ billion in M&A/licensing transactions, including Sanofi's acquisition of Genzyme and Bristol-Myers Squibb's acquisition of Amylin and the subsequent sale of 50% of Bristol's interest in Amylin to AstraZeneca. He began his Wall Street career as an Equity Research Analyst at Cowen and Company covering the biopharmaceutical sector. Prior to Cowen, he worked in biotech business development and began his career as a Research Scientist in the fields of musculoskeletal biology/gene therapy. He has been a Director at Vaccinex, Inc. since May 2013. Mr. Goater holds a B.A. in biology, an M.S. in pathology/molecular medicine, an M.S. in microbiology/immunology and an M.B.A., all from the University of Rochester.
Insufficient data for Jeff to compare compensation growth.
Jeff's remuneration is higher than average for companies of similar size in Germany.
Management Team Tenure
Average tenure and age of the
management team in years:
The tenure for the Surface Oncology management team is about average.
CEO, President & Director
Chief Scientific Officer
Senior VP of Finance & Business Operations and Treasurer
Chief Technology Officer
Vice President of Investor Relations & Communications
Vice President of Human Resources
Chief Medical Officer
Chief Business Officer
Board of Directors Tenure
Average tenure and age of the
board of directors in years:
The average tenure for the Surface Oncology board of directors is less than 3 years, this suggests a new board.
Surface Oncology, Inc., a clinical-stage immuno-oncology company, engages in the development of cancer therapies. The company develops human immunoglobulin isotype G4 monoclonal antibodies, including SRF231 inhibiting CD47; NZV930 inhibiting CD73; SRF617 inhibiting CD39; and SRF388 targeting interleukin 27. It also develops various earlier stage programs that targets other critical components of the tumor microenvironment, including regulatory T cells and natural killer cells. The company has a strategic collaboration agreement with Novartis Institutes for Biomedical Research, Inc. for the development of cancer therapies. Surface Oncology, Inc. was founded in 2014 and is headquartered in Cambridge, Massachusetts.
Simply Wall Street Pty Ltd (ACN 600 056 611), is a Corporate Authorised Representative (Authorised Representative Number: 467183) of Sanlam Private Wealth Pty Ltd (AFSL No. 337927). Any advice contained in this website is general advice only and has been prepared without considering your objectives, financial situation or needs. You should not rely on any advice and/or information contained in this website and before making any investment decision we recommend that you consider whether it is appropriate for your situation and seek appropriate financial, taxation and legal advice. Please read our Financial Services Guide before deciding whether to obtain financial services from us.